1. 360-Degree Perspectives on Biosimilars in Oncology

4. Definition of Biosimilars

5. History of Biosimilars Development

6. Why the Need for Oncology Biosimilars?

7. Biosimilars Are Not the Same as Generics

8. Biosimilars and Drift

9. Patent Expirations of Oncology Agents

10. State of Biosimilar Oncology Development

11. Regulatory Requirements for Oncology Biosimilars

12. Oncology Biosimilar Clinical Studies: Endpoints

13. Extrapolation of Indications

14. Interchangeability of Biosimilars

15. Naming of Biosimilar Products

16. Supportive Care Biosimilar: Filgrastim

17. Therapeutic Oncology Biosimilars: Trastuzumab

18. Therapeutic Oncology Biosimilars: Bevacizumab and Rituximab

19. Postmarketing Safety

20. Summary and Conclusions

21. Abbreviations